foscarnet has been researched along with Leukemia in 4 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angarone, M | 1 |
| Ison, MG | 1 |
| Bacigalupo, A | 1 |
| van Lint, MT | 1 |
| Tedone, E | 1 |
| Moro, F | 1 |
| Sanna, MA | 1 |
| Longren, M | 1 |
| Trespi, G | 1 |
| Frassoni, F | 1 |
| Occhini, D | 1 |
| Gualandi, F | 1 |
| Peggs, KS | 1 |
| Preiser, W | 1 |
| Kottaridis, PD | 1 |
| McKeag, N | 1 |
| Brink, NS | 1 |
| Tedder, RS | 1 |
| Goldstone, AH | 1 |
| Linch, DC | 1 |
| Mackinnon, S | 1 |
| Akesson-Johansson, A | 1 |
| Lernestedt, JO | 1 |
| Ringdén, O | 1 |
| Lönnqvist, B | 1 |
| Wahren, B | 1 |
1 review available for foscarnet and Leukemia
| Article | Year |
|---|---|
Prevention and early treatment of opportunistic viral infections in patients with leukemia and allogeneic stem cell transplantation recipients.
Topics: Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Herpes Zoster; | 2008 |
2 trials available for foscarnet and Leukemia
| Article | Year |
|---|---|
Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Topics: Adult; Anemia, Aplastic; Antigens, Viral; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovi | 1994 |
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
1 other study available for foscarnet and Leukemia
| Article | Year |
|---|---|
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Topics: Acyclovir; Adolescent; Adult; Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cycl | 2000 |